ã¡ãã£ã¢èšäº
æ¥çš®åŸã®è¡æ çãä»çµã¿è§£æãã¢ã¹ãã©è£œãè±ããŒã
ããºãææ°ããŒã¯ 311
twitterã³ã¡ã³ã 122ä»¶äž 1ïœ100件
ãã€ãã®äºããã©ãå
容ã¹ã«ã¹ã«ãªèšäºããªâŠâŠ
ã¡ãããšå®éšããŠäºå®ãå
¬è¡šããããšã¯è©äŸ¡ãã¹ãã ãªã
ã ãé¡ãã§ã
ãè¬ç©ã®ä»çµã¿ãå¹æãç解ããäžã§
䜿çšèš±å¯ãç³è«ããŠãã ãããã
æ¥æ¬æ¿åºã
ãã解ããªãç©ã®ç·æ¥äœ¿çšèš±å¯ãåºããªãã§äžãã
ãè¬ç©ã®ä»çµã¿ãå¹æãç解ããäžã§
䜿çšèš±å¯ãç³è«ããŠãã ãããã
æ¥æ¬æ¿åºã
ãã解ããªãç©ã®ç·æ¥äœ¿çšèš±å¯ãåºããªãã§äžãã
èªãã ããè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããããããã§è§£æããã£ãŠå®£èšã§ããç©ãªã®ïŒ
æãã£ããæ¡å€§è§£éããŠèšäºã«ããŠãã®ïŒ
çŽ äººãªã®ã§åããã
æãã£ããæ¡å€§è§£éããŠèšäºã«ããŠãã®ïŒ
çŽ äººãªã®ã§åããã
âè±ã¢ã¹ãã©ãŒãã«è£œã®æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ãæ¥çš®åŸããŸãã«è¡æ çãåŒãèµ·ããä»çµã¿ã®äžç«¯ã解æãããšãè±ã«ãŒãã£ã倧ãªã©ã®ããŒã ã2æ¥ãŸã§ã«ç±³ç§åŠèªãµã€ãšã³ã¹ã»ã¢ããã³ã·ãºã«çºè¡šâ
åçåŽåçã¯ä»å¹Žã®æ¥å€ã«ãããNew England journal of medicineãã®è«æãåŒçšãåå ãçºè¡šããŠããã40æ³ä»¥äžãä»ã¯ã¯ãã³ã§ã¢ã¬ã«ã®ãŒãèµ·ãã人以å€ã®æ¥çš®ã¯èªãã察çã¯ããŠããšèšããã
èšäºãéäžã§åããŠãæãã§ç¶ããç¥ããã
ãã¯ã¿ãŒã®åé¡ã®å¯èœæ§ã¯ãããããã¯ã¯ãã³ãšèšã£ãŠããin vivoã§ãåé¡ãšããŠã¯éºäŒåæ²»ççšè£œåããšãæ¯æ§è©Šéšã®è©äŸ¡é£ãããã§ãïŒå人çãªææ³ïŒã
ã¢ã¹ãã©è£œã¯ã¯ãã³è¡æ ç
è¡æ¶²äžã®ã¿ã³ãã¯è³ª
ãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
è¡æ¶²äžã®ã¿ã³ãã¯è³ª
ãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
ãã¡ãŒã¶ãŒçã®è£œè¬äŒç€Ÿãæ¥æ¬åœã¯ïŒ
ããŸã å æé¢ä¿ãèªããã
ããŸã å æé¢ä¿ãèªããã
解æããŠè§£æ±ºããŠãã売ã£ãŠãã ããã
å
ç«ãããªããŠææãåå ã§è¯ãã£ãæãã ãª
ææãå€ããã°è¯ãã ãã
ææãå€ããã°è¯ãã ãã
ããã¯çå®å
¬éã«åããŠæå ±ãã
åå ã解æãããããšã§ããããªãå®å
šãªã¯ã¯ãã³éçºã«ã€ãªããããã°ãããç 究ã ã
ããããã®ãã¡ãããšå€æãããã®ã¯ãããïœã
ã¢ãã«ããšãã¡ã€ã¶ãŒã®æ¹ããåé¡ãç¡ããå ±åããŠã»ãã
ã¢ãã«ããšãã¡ã€ã¶ãŒã®æ¹ããåé¡ãç¡ããå ±åããŠã»ãã
ãé«æ§èœãªé»åé¡åŸ®é¡ã§ã«ãã»ã«ã®æ§é ã芳å¯ããããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããžãŒã芳å¯ãå
ã«ã·ãã¥ã¬ãŒã·ã§ã³ããŒã â¶
ããã¯ããããå¥ã®ã¯ã¯ãã³éçºã§ã圹ç«ã¡ãããªæ
å ±ã ãªãæ§æç©ã®ã·ãã¥ã¬ãŒã·ã§ã³ã§å¯åå¿ãèµ·ãããããªç©è³ªãäºæž¬ã§ããã°ãäžå¿
èŠãªå¯åå¿ãäºãæžå
ã§ããå¯èœæ§ãããã
ãŸã ãŸã è²ã
ã§ãŠãããã§ããã
è¥ãåãç¹ã«ç·ã®åéã¯ããã€ããªããšãã
è¥ãåãç¹ã«ç·ã®åéã¯ããã€ããªããšãã
â
ãã¯ã¯ãã³ãããå®å šã«æ¹è¯ãããã³ãã«ãªããšããŠãããã
ç¿ã®é¢šéªãŠã£ã«ã¹ãªããŠèº«äœã«ãããããªããã
ãã¯ã¯ãã³ãããå®å šã«æ¹è¯ãããã³ãã«ãªããšããŠãããã
ç¿ã®é¢šéªãŠã£ã«ã¹ãªããŠèº«äœã«ãããããªããã
ã¯ã¯ãã³ãããå®å
šã«æ¹è¯ãããã³ãã«ãªããšããŠãã
è¡å°æ¿ç¬¬â
£å åã掻æ§åããã®ããªãð€
ãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
ãæ¥çš®åŸã®è¡æ çã®ä»çµã¿ã解æããããã¯ããã£ãããããªããŠããããã§ãæ¥çš®ã矩ååããŠãããã ãããªãããšããå«ãªäºæã
è±ã«ãŒãã£ã倧åŠãªã©ã®ããŒã ã2æ¥ãŸã§ã«ç±³ç§åŠèªãµã€ãšã³ã¹ã»ã¢ããã³ã·ãºã«çºè¡šãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æã
è¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
ã€ã®ãªã¹ã¢ã¹ãã©ãŒãã«è£œ ã¯ã¯ãã³æ¥çš®åŸããŸãã«è¡æ çãåŒãèµ·ããä»çµã¿ã®äžç«¯ã解æãããšãã€ã®ãªã¹ã«ãŒãã£ã倧åŠãªã©ã®ããŒã ãã¢ã¡ãªã«ç§åŠèªã«çºè¡šããŸãããã¯ã¯ãã³ãããå®å
šã«æ¹è¯ãããã³ãã«ãªããšããŠããŸãã
å¯åå¿ã¯å®éã«æã£ãŠããããã®äººéãç ç²ã«ãªã£ãŠãããã¯ã¯ãã³ãå€æ°ã®äººãæ»ãªããã®ã¯ç§åŠçãªäºå®ã ããåœãååŽçããã³ãããªã©ã¯ç¥ã£ãŠãŠãç¥ããªãããªãããŠã¯ã¯ãã³ãæãããå¯åå¿æ»ãåŸéºçãèªããªãã§æ¥ãã蚎èšãå§ãŸããã
ããã¯éã«ãå ææ§ã蚌æãããšããããšã§ã¯ïŒâ
âè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æãããâ
ææ
ã¯é²æ©ããªããç§åŠã¯é²æ©ããã®ã§ãã°ããã
解æã§ããã®ãªããå³äžæ¢ã«ãããã
æ¹è¯ããã®ã¯ããŸãäžæ¢ã«ããŠããã ããã
æ¹è¯ããã®ã¯ããŸãäžæ¢ã«ããŠããã ããã
ãããªããšã§ããããã®äººãå¯åå¿ã§äº¡ããªã£ãã®ã ãããªããã
ãããŒã ã¯ãŸããé«æ§èœãªé»åé¡åŸ®é¡ã§ã«ãã»ã«ã®æ§é ã芳å¯ããããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æãããã
ããã®ã¯ã¯ãã³ã¯ãæ°åã³ãããŠã€ã«ã¹ã®äžéšã®èšèšå³ããµã«ã®ãããŠã€ã«ã¹ããäœã£ãã«ãã»ã«ã§å
ã¿ã现èã«éãå±ãããã
ãã¯ã¿ãŒãŠã€ã«ã¹ãç¡å®³ã§ã¯ãªãã£ãããšããããšã«ãªãã®ãããã
ããµã«ã®ãããŠã€ã«ã¹ããäœã£ãã«ãã»ã«âŠâŠã®æ§é ã芳å¯ããããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æã
ããµã«ã®ãããŠã€ã«ã¹ããäœã£ãã«ãã»ã«âŠâŠã®æ§é ã芳å¯ããããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æã
æšæ¥ãååŽçãããæ¥çš®ã«ããçšã«èµ·ããå¯èœæ§ãããããšçºè¡šã®ãã£ãè¡æ çã«ã€ããŠã
ã¢ã¹ãã©ãŒãã«ããã¯ã¯ãã³ã®å€åœ¢ãããšã«ã·ãã¥ã¬ãŒã·ã§ã³ã§ãåå ãæŽãã ããšã®å ±éã
äœå ã§ã®ã¯ã¯ãã³ã®æ¯ãèããŸã§ã·ãã¥ã¬ãŒã·ã§ã³ããã®ããåãã
ã¢ã¹ãã©ãŒãã«ããã¯ã¯ãã³ã®å€åœ¢ãããšã«ã·ãã¥ã¬ãŒã·ã§ã³ã§ãåå ãæŽãã ããšã®å ±éã
äœå ã§ã®ã¯ã¯ãã³ã®æ¯ãèããŸã§ã·ãã¥ã¬ãŒã·ã§ã³ããã®ããåãã
ã³ã³ãã¥ãŒã¿ã§ã®ã·ã¥ãã¬ãŒã·ã§ã³ã§è§£æã§ãã蟺ãããã£ã±ããããŸã§ã®ããŒã¿ã®ç©ã¿éããšæè¡ã®çºå±äžã
æ³ã ãªã
ãããã£ãŠæ¹è¯ãé²ãã§ãããããªã£ãŠ
ãããã£ãŠæ¹è¯ãé²ãã§ãããããªã£ãŠ
ä»çµã¿è§£æããããããããããªã»ã»ã»ã
12/3(é)
ã¯ã¯ãã³ã¯å±ãªãã»ã£ãŠèšãåã£ãŠãçããã®é€é£ãã
ä»ã®ã¯ã¯ãã³ã«ãå±éºæ§ïŒã£ãŠããã€ãã®ç§åŠè ã
ãã
å®ç§ãªã®åŸ ã£ãŠããïŒå©ãã人ãå©ãããªãã»ãŠã®ãã
ãããã3åç®ã®éç¥ãæ¥ãã
ç¿ã¯ã»ã
ã¯ã¯ãã³ã¯å±ãªãã»ã£ãŠèšãåã£ãŠãçããã®é€é£ãã
ä»ã®ã¯ã¯ãã³ã«ãå±éºæ§ïŒã£ãŠããã€ãã®ç§åŠè ã
ãã
å®ç§ãªã®åŸ ã£ãŠããïŒå©ãã人ãå©ãããªãã»ãŠã®ãã
ãããã3åç®ã®éç¥ãæ¥ãã
ç¿ã¯ã»ã
çœé£ã¯å¿ããé ã«èšªãã
ãŠã£ã«ã¹ããäœãããã«ãã»ã«ããè¡å°æ¿ãšçµåããããæ§é ã ã£ããããªã
å®å
šã«ãªã£ãèš³ã§ã¯æããŸããã
ããã®ãã
(â§âœâŠ)
ããã®ãã
(â§âœâŠ)
ããŸãã«è¡æ çãåŒãèµ·ããä»çµã¿ã
çšãªã±ãŒã¹ã«é¢ããåå ã解æã
äœã®å ±åã ããæãªã®ããªã
çšãªã±ãŒã¹ã«é¢ããåå ã解æã
äœã®å ±åã ããæãªã®ããªã
è¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããã
åå ããããã°å¯Ÿçãç«ãŠããããªããããã°ã人é¡ã
"ãããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã"
ã¢ã¹ãã©ãŒãã«ã®ãã€ã¯çµå±ãæ¥æ¬ã§ã¯äœ¿ã£ãŠãªããã ããïŒ
æ¥ã«è§£æãïŒãã¢ãã¯å士ã®æ°Žé
žåã°ã©ãã§ã³ã®
説æãUPãããé端ïŒ
説æãUPãããé端ïŒ
çŽ æŽãããð
ãããå
±åéä¿¡ã説æãã£ãããããã
å ãã¿(è±æ)âåç §ã
Scientists identify reaction that may cause rare blood clots after AstraZeneca Covid vaccine
å ãã¿(è±æ)âåç §ã
Scientists identify reaction that may cause rare blood clots after AstraZeneca Covid vaccine
ã¢ã¹ãã©ãŒãã«ã®ã¯ã¯ãã³ã¯ããããæ¹è¯ãããæãã«ãªããã§ãããâŠïŒ
åŸåºã
ïŒã»ã»ïŒ
è¡æ ãã§ãããããšèšãããAZ補ã¯ã¯ãã³ã
æ¥ã æ¹è¯ã¯é²ãã
æ¥ã æ¹è¯ã¯é²ãã
è¡æ ã«èµ·å ããã¯ã¯ãã³æ¥çš®æ害äºè±¡ã¯ãã¹ãŠäºé²æ¥çš®å¥åº·è¢«å®³ææžå¶åºŠãé©çšãã¹ãã
ãæ²»éšã§è©Šããªããäœã§ãããªåé¡ãæ®ããŠèªå¯ããã®ïŒã
ããæããããããŸããããå šäººé¡ã§è©Šããããã§ã¯ãªããããäžç¢ºå®èŠçŽ ãããã®ã¯æ³å®ããŠãããããªãããªããšã¯æããŸããã
ããæããããããŸããããå šäººé¡ã§è©Šããããã§ã¯ãªããããäžç¢ºå®èŠçŽ ãããã®ã¯æ³å®ããŠãããããªãããªããšã¯æããŸããã
ä»æŽãå æé¢ä¿åŠå®ã§ããªãïŒ
ãã£ãšå æé¢ä¿ãèªããããã§ãããæ¢ã«è¡æ çãåŒãèµ·ããä»çµã¿ã解æãããŠãŸãã
é ããã§ããã
ãã£ãšå æé¢ä¿ãèªããããã§ãããæ¢ã«è¡æ çãåŒãèµ·ããä»çµã¿ã解æãããŠãŸãã
é ããã§ããã
21äžçŽãçç¥ã§ããð(ã¯ããã)
现ããªçŸè±¡ã¯èšäºèªãã§ãããããªããã©ã解決ã«åãããªãäœãã
ãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããã
äœãïŒ æèãããããšæåãã®ãã®ã§ã¯ãªãã«ãã»ã«ã®æåããªã
äœãïŒ æèãããããšæåãã®ãã®ã§ã¯ãªãã«ãã»ã«ã®æåããªã
ããå®å
šã«ãªããªããããããã
ãã®ã¯ã¯ãã³ã¯ããè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ãããã
ããªããªãŒã·ã¹ãã ã«åå ïŒ
ðã¯ã¯ãã³ãã®ãã®ã§ãªã
å©å€ãåå ãªã®ã ãšããã
解決ã¯æ©ããããð€
â
å©å€ãåå ãªã®ã ãšããã
解決ã¯æ©ããããð€
â
ãããâŠ
ã¡ã¢
ããã§ããå®å šã«ãªããããã®çºèŠãæ°ããåµè¬ã®ãã³ãã«ããªãã®ã ããã
"
ããã§ããå®å šã«ãªããããã®çºèŠãæ°ããåµè¬ã®ãã³ãã«ããªãã®ã ããã
"
æ²»éšäžã ããã
ããããªäººã«æ¥çš®ããŠå®éšå°ã«ãããããã
ããŒã¿ã沢山åããŠæ¹è¯ãåºæ¥ããã
æ¬æ¥æ²»éšã«ã¯åå è ã«ãéæããã ãã©ãä»åã¯æªå®æã®ã¯ã¯ãã³ã売ããŠå²ããããŠããŠãã ã£ãããã ã
ããããªäººã«æ¥çš®ããŠå®éšå°ã«ãããããã
ããŒã¿ã沢山åããŠæ¹è¯ãåºæ¥ããã
æ¬æ¥æ²»éšã«ã¯åå è ã«ãéæããã ãã©ãä»åã¯æªå®æã®ã¯ã¯ãã³ã売ããŠå²ããããŠããŠãã ã£ãããã ã
åå
žèªãŸãªããšãçååŠçãªã¢ãã»ã€ã¯ãã¡ãããã£ãŠããã ããïŒ
é«æ§èœãªé»åé¡åŸ®é¡ã§ã«ãã»ã«ã®æ§é ã芳å¯ããããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
ããšãã¢ã¹ãã©ãŒãã«è£œã®ã¯ã¯ãã³ãæ¥çš®ããåŸã®è¡æ çããã£ãšæ°ã«ã¯ãªã£ãŠããããå°ããã€è§£æãããŠããã®ã¯è¯ãäºã ãã©ããŸãã¯ã¯ãã³ã«å¯Ÿããäžè«ãšããå€ãããããªæ°ããããª
ãé«æ§èœãªé»åé¡åŸ®é¡ã§ã«ãã»ã«ã®æ§é ã芳å¯ããããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æãïŒ
ã»ããŒãã¢ã¹ãã©ãŒãã«ãã¡ãããšèª¿ã¹ãŠãããŠãã£ãŠããŒã
âŠãŸããèšããŠããã¡ã€ã¶ãŒãšã¢ãã«ãã®å¿çççºçã®å¯èœæ§ã¯ã¢ã¹ãã©ãŒãã«ã®è¡æ ççºç確çãšã©ã£ããã©ã£ããã¿ããã ã£ããã©ãªã
âŠãŸããèšããŠããã¡ã€ã¶ãŒãšã¢ãã«ãã®å¿çççºçã®å¯èœæ§ã¯ã¢ã¹ãã©ãŒãã«ã®è¡æ ççºç確çãšã©ã£ããã©ã£ããã¿ããã ã£ããã©ãªã
解æãããªããŠã確èªããã
誰ã詳现ãªè§£èª¬ãããŠãããã®ãåŸ
ãšã
èŠããã«æ§é äžã®åé¡ã ã£ãããã§ãçŸç¶ã®ã¢ã¹ãã©ãŒãã«è£œã¯ã¯ãã³ã¯ãã¹ãŠãã®ããã ããå
å
ããŠããããšãããããã
COVID-19èªäœè¡æ ãã§ããããäºãšå¥ã ã£ãã®ã
èšäºãçŽ çŽã«èªããšãåé¡ã¯ã«ãã»ã«ã«ãã£ãŠã¯ã¯ãã³ã®éºäŒæ
å ±ãéºäŒæ
å ±ãããããå
ç«å¹æã«ã¯ãªãããã«èªãããã©ããããªã®ïŒ QT
補(ã€ã®ãªã¹)ã®æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ãæ¥çš®åŸãçšã«è¡æ çãåŒãèµ·ããä»çµã¿ã®äžç«¯ã解æãããšãã«ãŒãã£ã倧åŠçã®ããŒã ããç§åŠèªãµã€ãšã³ã¹ã»ã¢ããã³ã·ãºã«çºè¡šãããã¯ã¯ãã³ãããå®å
šã«æ¹è¯ãããã³ãã«ãªããšããŠããã è¡å°æ¿ç¬¬4å å(PF4)ïŒ
ð¥
ïŒðãããå®å šã«æ¹è¯ãããã³ãã«ãªã
ã¯âïžãã³ãâïž
ããããæ¹è¯ããã®âïž
æ¢ã«æã£ãŠäº¡ããªã£ãæ¹ã ã¯çãè¿ããŸããã
ã ãããŸã æ²»éšäžãªãã ã£ãŠããšãããå æžèªèããŸãããã
ãããã£ãŠäººäœå®éšããŠããã ãã
ïŒðãããå®å šã«æ¹è¯ãããã³ãã«ãªã
ã¯âïžãã³ãâïž
ããããæ¹è¯ããã®âïž
æ¢ã«æã£ãŠäº¡ããªã£ãæ¹ã ã¯çãè¿ããŸããã
ã ãããŸã æ²»éšäžãªãã ã£ãŠããšãããå æžèªèããŸãããã
ãããã£ãŠäººäœå®éšããŠããã ãã
蚌æãããã°ãã¯ã¯ãã³ãå®å
šã«æ¹è¯ãããã³ãã«ãªããšåæã«ãå æé¢ä¿äžæã®å¯åå¿ã®äººéã®èª¿æ»ãåºæ¥ãããã«ãªã
ããã«ããŠãéã
ããã«ããŠãéã
ç§åŠçã«ã解æã§ãããäžæ©åé²ãå æé¢ä¿äžæã ããè£åããªãã®ã§ã¯ãªããçãããããªãè£åããã®ã倧äºãäžäžã®æã«èŠæšãŠãæ¹éã¯äžå®ãå©é·ããã
ãã¯ã¯ãã³äžæ¬è¢«ããã®åœãå¢ããŠããæãã§ãããå¯åå¿ã®è§£æãé²ãã§ããããã§ã
â
ïŒã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããïŒ
â
ïŒã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããïŒ
ã¯ã
>ãããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
>ãããåºã«ããã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
è¡æ çãèµ·ããããšã¯å
¬åŒã«èªããŠããã®ãª
ã¯ã¯ãã³ãããå®å
šã«æ¹è¯ãããã³ãã«ãªããšããŠããã
â
ããããããããããããã
ããããŒã ã
ä»æŽïŒ
â
ããããããããããããã
ããããŒã ã
ä»æŽïŒ
人æºãšåªåã®çŽ æŽããããæããã
ãã®äº¡ããªã£ãBBCã®ã©ãžãªåžäŒè
ã®æ¹ã¯ããŸãã«ã¢ã¹ãã©ãŒãã«ã¯ã¯ãã³ã®è¢«å®³è
ãšããããšã
>è¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
確ãã¢ã¹ãã©ãŒãã«ãšå
æ¬é£æºç· çµããŠããããŸããã
ã¢ã¹ãã©ãŒãã«ãæ¥çš®åŸã®è¡æ çãä»çµã¿è§£æ
ã¢ã¹ãã©ãŒãã«ãæ¥çš®åŸã®è¡æ çãä»çµã¿è§£æ
ããããç 究ãæªæ¥ã®ã¯ã¯ãã³ã«ããè¯ãçµæãããããã
ã ãã倧äº
ã ãã倧äº
ãããmRNAã¯ã¯ãã³ã®æ¹ã®å¿ççãšã®å æé¢ä¿ãæ©ããšã解æããŠããªãŒãºã
ããð¶ ãã£ãšè§£æãé²ã¿ãŸãããã«ð€
ãã¯ã¯ãã³ãããå®å
šã«æ¹è¯ãããã³ãã«ãªããšããŠãããã
ãšã
ãšã
ããããããæ¹è¯ããã°è¯ããã ãªãã§ãå¹æãèœã¡ããšãªã£ããåé¡ã ããïœ
ãŠã€ã«ã¹ããäœããã€ã¯ãã«ãã»ã«ãªããŠã®ããããã ãã
AZã¯ã¯ãã³ã¯ã ã®äžéšã®èšèšå³ããµã«ã®ãããŠã€ã«ã¹ããäœã£ãã«ãã»ã«ã§å
ã¿ã现èã«éãå±ããã
ãã®ã«ãã»ã«ã®æ§é ããè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æ
ãã®ã«ãã»ã«ã®æ§é ããè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æ
é
ãã£ãŠïŒ
ãã³ã³ãã¥ãŒã¿ãŒã·ãã¥ã¬ãŒã·ã§ã³ã®çµæãè¡æ¶²äžã®ã¿ã³ãã¯è³ªãè¡å°æ¿ç¬¬4å åïŒPF4ïŒããšãã£ã€ããããããšãå€æããã
èŠå ããããã°æ¹åã®éã¯ã§ããã
èŠå ããããã°æ¹åã®éã¯ã§ããã
è¬å®³ã®ãšããã³ã¹ãâŠð
ãµãŒãã£ãŠæãã®ãã€ãŒãã
å㞠次ãž